This website uses cookies. By continuing you are agreeing to our privacy policy.

Dennis Adeegbe, Ph.D.

Dennis Adeegbe
H. Lee Moffitt Cancer Center & Research Institute
HDAC6 Inhibition and Treg-targeting as Immunotherapeutic Strategy for NSCLC
Lung Cancer Discovery Award

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in the United States and treatments that yield durable effects in the greater proportion of patients are still lacking. We recently found that a drug (ACY241) when administered promoted positive quantitative and qualitative changes in the immune cells within the tumors. In follow up studies, we seek to understand how this drug evokes these changes as better understanding of this is important for determining how it can be best used for therapeutic purposes. Another goal of this project is to determine if leveraging the immune-enhancing activity of this drug will be broadly therapeutic than existing treatments if it is combined with drugs that impair the activity of immune-suppressive T cells. These studies have important implications for patients' health in that any observed therapeutic effects beyond existing treatments could pave way for new strategies to combat lung cancer.

Red button with telephone
Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
Red button of two hand prints
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

Button of turquoise LUNG FORCE swirl
What is LUNG FORCE?

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.